Table_1_Comparison of 68Ga-FAPI and 18F-FDG PET/CT for the diagnosis of primary and metastatic lesions in abdominal and pelvic malignancies: A systematic review and meta-analysis.docx

dataset

posted on 2023-02-17, 05:05 authored by Xue Liu, Huiting Liu, Cailiang Gao, Wenbing Zeng

Purpose

The purpose of this study is to compare the application value of ⁶⁸Ga-FAPI and ¹⁸F-FDG PET/CT in primary and metastatic lesions of abdominal and pelvic malignancies (APMs).

Materials

The search, limited to the earliest available date of indexing through 31 July 2022, was performed on PubMed, Embase, and Cochrane Library databases using a data-specific Boolean logic search strategy. We calculated the detection rate (DR) of ⁶⁸Ga-FAPI and ¹⁸F-FDG PET/CT in the primary staging and recurrence of APMs, and pooled sensitivities/specificities based on lymph nodes or distant metastases.

Results

We analyzed 473 patients and 2775 lesions in the 13 studies. The DRs of ⁶⁸Ga-FAPI and ¹⁸F-FDG PET/CT in evaluating the primary staging and recurrence of APMs were 0.98 (95% CI: 0.95-1.00), 0.76 (95% CI: 0.63-0.87), and 0.91(95% CI: 0.61-1.00), 0.56 (95% CI: 0.44-0.68), respectively. The DRs of ⁶⁸Ga-FAPI and ¹⁸F-FDG PET/CT in primary gastric cancer and liver cancer were 0.99 (95% CI: 0.96-1.00), 0.97 (95% CI: 0.89-1.00) and 0.82 (95% CI: 0.59-0.97), 0.80 (95% CI: 0.52-0.98), respectively. The pooled sensitivities of ⁶⁸Ga-FAPI and ¹⁸F-FDG PET/CT in lymph nodes or distant metastases were 0.717(95% CI: 0.698-0.735) and 0.525(95% CI: 0.505-0.546), and the pooled specificities were 0.891 (95% CI: 0.858-0.918) and 0.821(95% CI: 0.786-0.853), respectively.

Conclusions

This meta-analysis concluded that ⁶⁸Ga-FAPI and ¹⁸F-FDG PET/CT had a high overall diagnostic performance in detecting the primary staging and lymph nodes or distant metastases of APMs, but the detection ability of ⁶⁸Ga-FAPI was significantly higher than that of ¹⁸F-FDG. However, the ability of ⁶⁸Ga-FAPI to diagnose lymph node metastasis is not very satisfactory, and is significantly lower than that of distant metastasis.

Systematic review registration

https://www.crd.york.ac.uk/prospero/, identifier CRD42022332700.